Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Biomed Res Int ; 2015: 786104, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26000303

RESUMO

We assessed the effect of a novel and selective phosphodiesterase 4 (PDE4) inhibitor, ciclamilast, on chronic inflammation in adjuvant-induced arthritis (AIA), a rat model of rheumatoid arthritis (RA), and acute inflammation in the rat and mouse model of carrageenan-induced paw edema and peritonitis. Our results showed that daily oral administration of ciclamilast at 1, 3, and 10 mg/kg dose-dependently inhibited the increase in hind paw volume of rats with AIA. The inhibition of paw edema was associated with inhibition of both the production of cytokines such as TNF-α, IL-1ß, and IL-6 and cell infiltration assessed in subcutaneous paw tissue. Moreover, there was significantly less tissue destruction in the ciclamilast-treated rats compared to the vehicle-treated rats, as assessed by radiographic analysis and histopathological evaluation. In the two acute inflammation models, ciclamilast inhibited carrageenan-induced paw edema in rats and inflammatory cell migration into the peritoneal cavity in mice in a dose-dependent manner. These results not only suggest that ciclamilast, as a disease-modifying antirheumatic drug (DMARD), can attenuate RA but also provide proof of principle that a PDE4 inhibitor may be useful for the treatment of arthritis.


Assuntos
Artrite Experimental/tratamento farmacológico , Benzamidas/uso terapêutico , Piridinas/uso terapêutico , Animais , Anti-Inflamatórios/farmacologia , Anti-Inflamatórios/uso terapêutico , Artrite Experimental/complicações , Artrite Experimental/diagnóstico por imagem , Artrite Experimental/patologia , Benzamidas/farmacologia , Peso Corporal/efeitos dos fármacos , Carragenina , Citocinas/metabolismo , Modelos Animais de Doenças , Feminino , Masculino , Camundongos Endogâmicos ICR , Tamanho do Órgão/efeitos dos fármacos , Peritonite/induzido quimicamente , Peritonite/complicações , Peritonite/tratamento farmacológico , Peritonite/patologia , Piridinas/farmacologia , Radiografia , Ratos Sprague-Dawley , Tela Subcutânea/efeitos dos fármacos
2.
Toxicol Mech Methods ; 24(8): 575-83, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25134437

RESUMO

Cigarette smoke contains reactive oxygen (ROS) that can cause oxidative stress. It increases the number of apoptotic and necrotic lung cells and further induces the development of chronic airway disease. In this study, we investigated the effects of cigarette smoke extract (CSE) on apoptosis in human bronchial epithelial cells (BEAS-2B). CSE exposure induced ROS generation and p38 mitogen-activated protein kinase (MAPK) activation that are associated with the activation of apoptosis-regulating signal kinase 1 (ASK-1). N-acetylcysteine (a general antioxidant) attenuated the CSE-induced ASK-1 and p38 MAPK activation and cell apoptosis, suggesting a triggering role of ROS in ASK-1/p38 MAPK activation during apoptotic progression. In contrast, the inhibition and knockdown of p38 attenuated the expression of anti-oxidant master NF-E2-related factor 2 (Nrf-2) and CSE-induced apoptosis, suggesting that p38 MAPK modulates Nrf-2 expression and presumably prevents cell apoptosis. Taken together, the data presented in this manuscript demonstrate that the ROS-dependent ASK-1/p38 signaling cascade regulates CSE-induced BEAS-2B cell apoptosis. In addition, anti-oxidative Nrf-2 is also up-regulated by the ROS/p38 signaling cascade in this progression.


Assuntos
Apoptose/efeitos dos fármacos , Brônquios/efeitos dos fármacos , Regulação da Expressão Gênica/efeitos dos fármacos , Fator 2 Relacionado a NF-E2/agonistas , Mucosa Respiratória/efeitos dos fármacos , Fumar/efeitos adversos , Regulação para Cima/efeitos dos fármacos , Acetilcisteína/farmacologia , Elementos de Resposta Antioxidante/efeitos dos fármacos , Antioxidantes/farmacologia , Brônquios/enzimologia , Brônquios/metabolismo , Linhagem Celular , Misturas Complexas/antagonistas & inibidores , Misturas Complexas/toxicidade , Ativação Enzimática/efeitos dos fármacos , Inativação Gênica , Humanos , MAP Quinase Quinase Quinase 5/antagonistas & inibidores , MAP Quinase Quinase Quinase 5/química , MAP Quinase Quinase Quinase 5/metabolismo , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Fator 2 Relacionado a NF-E2/antagonistas & inibidores , Fator 2 Relacionado a NF-E2/genética , Fator 2 Relacionado a NF-E2/metabolismo , Espécies Reativas de Oxigênio/agonistas , Espécies Reativas de Oxigênio/metabolismo , Mucosa Respiratória/enzimologia , Mucosa Respiratória/metabolismo , Fumaça , Produtos do Tabaco , Proteínas Quinases p38 Ativadas por Mitógeno/antagonistas & inibidores , Proteínas Quinases p38 Ativadas por Mitógeno/química , Proteínas Quinases p38 Ativadas por Mitógeno/genética , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
3.
JPEN J Parenter Enteral Nutr ; 31(5): 358-64; discussion 364-5, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17712143

RESUMO

BACKGROUND: Mucosal addressin cellular adhesion molecule-1 (MAdCAM-1) directs lymphocyte migration into gut-associated lymphoid tissue (GALT) through Peyer's patches (PPs). Parenteral nutrition (PN) impairs mucosal immunity by reducing PPs MAdCAM-1 expression, T and B cells in GALT, and intestinal and respiratory immunoglobulin (Ig) A levels. We previously showed that PN reduces lymphotoxin beta receptor blockade (LTbetaR) in PPs and intestine, and that stimulation with LTbetaR agonist antibodies reverses these defects. To confirm that LTbetaR regulates transcription of MAdCAM-1 message and more fully understand the effects of LTbetaR on MAdCAM-1 function within the mucosal immune system, we studied the effect of LTbetaR blockade with a chimeric LTbetaR Ig-fusion protein on MAdCAM-1 mRNA levels, PP lymphocyte mass and IgA levels in the intestinal and respiratory tracts. METHODS: Mice were cannulated and killed 3 days after receiving chow + control Ig, chow + LTbetaR-Ig fusion protein (100 microg IV), or PN + control Ig. The PPs of half of the animals were processed for lymphocyte count, and the other half were processed for complementary DNA and subsequent polymerase chain reaction (PCR). mRNA levels of MAdCAM-1 were determined by real-time PCR; intestinal and respiratory IgA levels were measured by ELISA. RESULTS: PN significantly reduced PP lymphocyte mass, MAdCAM-1 mRNA, and intestinal IgA. As anticipated, LTbetaR blockade significantly decreased PP cells and MAdCAM-1 mRNA, but not intestinal IgA because chow feeding was maintained. Both LTbetaR blockade and PN decreased nasal IgA, but not significantly. CONCLUSIONS: LTbetaR blockade in chow animals significantly reduces transcription of MAdCAM-1 gene and PPs lymphocyte mass. These data implicate inadequate LTbetaR signaling as a major mechanism for decreased GALT cells with lack of enteral stimulation, and further establish the role of LTbetaR in the mucosal immune system.


Assuntos
Imunidade nas Mucosas , Imunoglobulina A/imunologia , Imunoglobulinas/metabolismo , Receptor beta de Linfotoxina/antagonistas & inibidores , Mucoproteínas/metabolismo , Nutrição Parenteral/efeitos adversos , Nódulos Linfáticos Agregados/imunologia , Animais , Moléculas de Adesão Celular , Ensaio de Imunoadsorção Enzimática/métodos , Regulação da Expressão Gênica , Humanos , Imunidade nas Mucosas/fisiologia , Imunoglobulina A/biossíntese , Intestino Delgado/imunologia , Contagem de Linfócitos , Receptor beta de Linfotoxina/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos ICR , Nódulos Linfáticos Agregados/citologia , Nódulos Linfáticos Agregados/metabolismo , Reação em Cadeia da Polimerase/métodos , RNA Mensageiro/metabolismo , Distribuição Aleatória
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA